, 3 mois). Les autres études duraient minimum 18 mois. 2 études duraient 3 ans (Durrieu, Seule 1 étude sur les 9 sélectionnées ne duraient que quelques mois, 1999.
, Les Entreprises du Médicaments LEEM. Les essais cliniques en 10 questions
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results, Trials, vol.16, issue.3, 2015. ,
Agence nationale de sécurité du médicament et des produits de santé ,
, Annual Report on EudraVigilance for the European Parliament, the Council and the Commission, 2016.
Under-reporting of adverse drug reactions : a systematic review, Drug Saf, vol.29, issue.5, pp.385-96, 2006. ,
, Conseil National de l'Ordre des Médecins, vol.326, 2016.
, ANSM. Bulletins des vigilances -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2016.
,
Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews, Int J Technol Assess Health Care, vol.21, issue.3, pp.380-385, 2005. ,
Impact of educational interventions on adverse drug events reporting, Int J Technol Assess Health Care, vol.29, issue.4, pp.410-417, 2013. ,
Strategies to Improve Adverse Drug Reaction Reporting: A Critical and Systematic Review, Drug Saf. mai, vol.36, issue.5, pp.317-345, 2013. ,
A general practitioner's one year record of adverse drug reactions ,
, Therapie. juin, vol.67, issue.3, pp.237-279, 2012.
Événements indésirables en médecine générale, enquête nationale en soins primaires, Soins. avr, vol.61, issue.804, pp.20-22, 2016. ,
, Assurance Maladie. ameli.fr -Activité et prescriptions
Pharmacoeconomics of adverse drug reactions, Fundam Clin Pharmacol. juin, vol.18, issue.3, pp.275-80, 2004. ,
The economic burden of preventable adverse drug reactions: a systematic review of observational studies, Expert Opin Drug Saf. 3 juill, vol.17, issue.7, pp.681-95, 2018. ,
, Commission of the European Communities : Staff Working Document : Impact assesment of PV, 2008.
A short history of thalidomide embryopathy, Teratology. sept, vol.38, issue.3, pp.203-218, 1988. ,
, ). veille sanitaire, agences sanitaires, afssa, afsset, afssaps, invs, efs, abm, -Politiques publiques -repères -vie-publique.fr, Veille et évaluation des risques sanitaires, La sécurité sanitaire, 1990.
,
, Rapport sur l'application de la loi n° 98-535 du 1er juillet 1998 relative au renforcement de la veille sanitaire et du contrôle de la sécurité sanitaire des produits destinés à l'homme
Comment éviter les prochaines affaires Vioxx, 2005. ,
, Enquête sur le MEDIATOR -IGAS -Inspection générale des affaires sociales
, Arnaud Robinet sur le projet de loi , après engagement de la procédure accélérée, relatif au renforcement de la sécurité sanitaire du médicament et des produits de santé (n°3714, N° 3725 -Rapport de M
,
, Répertoire des spécialités pharmaceutiques, ANSM -Accueil
, Annual Report on EudraVigilance for the European Parliament, the Council and the Commission, vol.25, 2018.
,
Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009, Eur J Clin Pharmacol. juill, vol.68, issue.7, pp.1057-63, 2012. ,
29. selincro-PSUSA-00010120-201408-scientific conclusions grounds recommending variation ,
Causes for the underreporting of adverse drug events by health professionals: a systematic review, Rev Esc Enferm USP. août, vol.48, issue.4, pp.739-786, 2014. ,
Determinants of Under-Reporting of Adverse Drug Reactions, Drug Saf. janv, vol.32, issue.1, pp.19-31, 2009. ,
, List of All Journals Cited in PubMed®
,
LibGuides: Web of Science platform: Web of Science: Summary of Coverage ,
, Biomedical research -Embase
ABES : Catalogue Sudoc Public -Catalogue Sudoc public -Sudoc ,
, Disponible sur
Guidelines for snowballing in systematic literature studies and a replication in software engineering, Proceedings of the 18th International Conference on Evaluation and Assessment in Software Engineering -EASE '14 ,
, , pp.1-10, 2014.
Attitudes to adverse drug reaction reporting, Br J Clin Pharmacol. mai, vol.41, issue.5, pp.434-439, 1996. ,
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration, PLoS Med. 21 juill, vol.6, issue.7, p.1000100, 2009. ,
, Niveau de preuve et gradation des recommandations de bonne pratique, HAS
A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme, Br J Clin Pharmacol. août, vol.60, issue.2, pp.221-224, 2005. ,
La notification d'effet indésirable au secours de l'ordonnance « non substituable » ! Therapie, juin, vol.69, issue.3, pp.259-61, 2014. ,
Effectiveness of Pharmacovigilance Training of General Practitioners A Retrospective Cohort Study in the Netherlands Comparing Two Methods, Drug Saf, vol.34, issue.9, pp.755-62, 2011. ,
Evaluation of a new pharmacovigilance tool: simplified online reporting for general practitioners, Sante Publique (Bucur). avr, vol.30, issue.2, pp.225-257, 2018. ,
Apport de la visite d'assistants de recherche clinique aux cabinets de médecins généralistes sur la notification des effets indésirables médicamenteux, Therapie. juin, vol.72, issue.3, pp.351-356, 2017. ,
La déclaration des effets indésirables médicamenteux en médecine générale: étude descriptive sur une période de trois mois évaluant l'intérêt d'une fiche de déclaration simplifiée, 2007. ,
Un nouvel outil de notification des effets indésirables médicamenteux à destination des médecins généralistes en Midi-Pyrénées: www.mediceo.fr, 2009. ,
Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region), Eur J Clin Pharmacol. févr, vol.69, issue.2, pp.237-281, 2013. ,
Educational intervention to improve physician reporting of adverse drug reactions (ADRs) in a primary care setting in complementary and alternative medicine, BMC Public Health. 31 juill, vol.9, p.274, 2009. ,
A small economic inducement to stimulate increased reporting of adverse drug reactions--a way of dealing with an old problem?, Eur J Clin Pharmacol. mai, vol.62, issue.5, pp.381-386, 2006. ,
Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports, Eur J Clin Pharmacol. mai, vol.65, issue.5, pp.511-515, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00534937
Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study, BMC Clin Pharmacol, vol.11, p.14, 2011. ,
Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac (TM)): A randomized controlled trial, Vaccine. 29 sept, vol.32, issue.43, pp.5662-5670, 2014. ,
An educational intervention to improve physician reporting of adverse drug reactions: a clusterrandomized controlled trial, JAMA. 6 sept, vol.296, issue.9, pp.1086-93, 2006. ,
Effect of an educational intervention to improve adverse drug reaction reporting in physicians: a cluster randomized controlled trial, Drug Saf. févr, vol.38, issue.2, pp.189-96, 2015. ,
Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor, Eur J Clin Pharmacol. mai, vol.63, issue.5, pp.505-513, 2007. ,
Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads, Drug Saf, vol.26, issue.14, pp.1049-55, 2003. ,
Workshop-and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal, Drug Saf. 1 août, vol.35, issue.8, pp.655-65, 2012. ,
Improving adverse drug reaction reporting in portuguese health professional : case-control studies and cluster-randomized trial, 2005. ,
An approach to increase adverse drug events reports in Mercosur, Afr J Pharm Pharmacol. 8 déc, vol.9, issue.45, pp.1062-70, 2015. ,
Impact of series of interventions on clinicians' awareness about pharmacovigilance system in Western India, Asian J Pharm Clin Res. 1 janv, vol.7, pp.14-20, 2014. ,
Pharmacovigilance: Our experience in Aden, World J Pharm Sci, vol.6, issue.11, pp.57-61, 2018. ,
Strengthening the Pharmacovigilance Programme in Nepal, Nepal J Epidemiol. 30 mars, vol.3, issue.1, pp.230-235, 2013. ,
Teaching pharmacovigilance to medical students and doctors, Indian J Pharmacol. 9 janv, vol.38, issue.5, p.316, 2006. ,
Utilisation d'un module semi-automatique de déclaration des effets indésirables médicamenteux: une proposition pour simplifier la démarche du médecin généraliste, 2014. ,
Exploitation systématique de la iatrogénie identifiée en Médecine Générale à des fins de Pharmacovigilance, 2015. ,
Reporting adverse drug reactions in an ambulatory care setting, Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 déc, vol.52, issue.23, pp.2704-2710, 1995. ,
Saudi Vigilance Program: Challenges and lessons learned, Saudi Pharm J. 1 mars, vol.26, issue.3, pp.388-95, 2018. ,
Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting, Drug Saf, vol.41, issue.5, pp.511-515, 2018. ,
Physicians' knowledge and attitude towards adverse event reporting system and result to intervention--randomized nested trial among Bulgarian physicians, Med Glas Off Publ Med Assoc Zenica-Doboj Cant Bosnia Herzeg. août, vol.10, issue.2, pp.365-72, 2013. ,
Interventions for sustained healthcare professional behaviour change: a protocol for an overview of reviews, vol.5, 2016. ,
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias, PLoS ONE, vol.3, issue.8, 2008. ,
,
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy, Drug Saf, vol.31, issue.7, pp.609-625, 2008. ,
,
No magic bullets: a systematic review of 102 trials of interventions to improve professional practice, CMAJ Can Med Assoc J J Assoc Medicale Can, vol.153, issue.10, pp.1423-1454, 1995. ,
Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance, J Public Health. août, vol.21, issue.4, pp.365-72, 2013. ,
Comparative evaluation of adverse drug reaction reporting forms for introduction of a spontaneous generic ADR form, J Pharmacol Pharmacother, vol.3, issue.3, p.228, 2012. ,
The Form Of The Form, 2014. ,
Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature, Eur J Clin Pharmacol. oct, vol.74, issue.10, pp.1235-1283, 2018. ,
Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study, Drug Saf, vol.40, issue.5, pp.409-427, 2017. ,
Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records, Drug Saf. 1 sept, vol.35, issue.9, pp.733-776, 2012. ,
Incidence and Costs of Adverse Drug Reactions During Hospitalisation: Computerised Monitoring Versus Stimulated Spontaneous Reporting, Drug Saf, vol.22, issue.2, pp.161-170, 2000. ,
Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting, Pharmacoepidemiol Drug Saf. déc, vol.19, issue.12, pp.1211-1216, 2010. ,
The usefulness of listening social media for pharmacovigilance purposes: a systematic review, Expert Opin Drug Saf. nov, vol.17, issue.11, pp.1081-93, 2018. ,
Uppsala Monitoring Centre Annual Report, 2017. ,